Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CVX-060 |
Trade Name | |
Synonyms | PF-04856884 |
Drug Descriptions |
CVX-060 (PF-04856884) is a peptide-antibody fusion protein that targets Angiopoeitin-2 (Ang2), resulting in decreased angiogenesis, and potentially leading to decreased tumor growth (PMID: 21233403, PMID: 27651308). |
DrugClasses | |
CAS Registry Number | 1415649-10-3 |
NCIT ID | C116625 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + CVX-060 | Bevacizumab CVX-060 | 0 | 0 |
CVX-060 | CVX-060 | 0 | 0 |
CVX-060 + Regorafenib | CVX-060 Regorafenib | 0 | 0 |
CVX-060 + Sorafenib | CVX-060 Sorafenib | 0 | 0 |
CVX-060 + Sunitinib | CVX-060 Sunitinib | 0 | 0 |